OBJECTIVES: To present three-months results on treatments prescribed and their impact on the clinical aspects and Quality of Life (QoL) of children and adolescents with ADHD. METHODS: ADORE, a 2-year, prospective, observational study in Attention Deficit/ Hyperactivity Disorder (ADHD) enrolling patients across 10 European countries. ADORE main objective is to describe the relationship between treatment prescribed and QoL of ADHD, in actual practice, over a two-year period. Patients were enrolled if in the opinion of the investigator showed hyperactive/ inattentive/ impulsive symptoms. QoL was measured with the Child Health and Illness Profile (CHIP-CE). Clinical ADHD specific and generic outcomes were measured with ADHD-RS, CGI-Severity, SDQ, and CGAS. Other outcomes included parent's health problems, truancy, and social invites. Treatments were classified as pharmacotherapy, psychotherapy, pharmacotherapy and psychotherapy combination, other, and none. All results presented are descriptive. Percentages were calculated based on the number of patients who answered the question of interest. RESULTS: A total of 1478 eligible patients were analysed. Overall mean age (sd) for patients was 9.0 years (2.5), 84% of them being male. At baseline, 270 patients (19%) were prescribed psychotherapy, 360 (25%) pharmacotherapy, 356 (25%) pharmacotherapy and psychotherapy combination, 148 (10%) other therapy, and 294 (21%) nothing. At 3 months, nearly 70% of the patients were receiving either pharmacotherapy (442 [40.0%]) or its combination with psychotherapy (310 [28.1%]). Baseline mean CGI-Severity score (SD) was 4.4 (0.9) for the overall group with no major differences between the treatment regimens. At 3 months, the biggest improvement was seen in the patients receiving pharmacotherapy (-1.3 [1.1]) followed by combination (-1.1 [1.1]). Results were consistent across scales (ADHD-RS, SDQ, CGAS, CHIP-CE). CONCLUSIONS: Presented information suggests that, on average, patient's receiving pharmacotherapy or its combination with psychotherapy experienced greater improvements over the first three months in the study.